• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.

ENZ (Enzo Biochem Inc)
Last Trade 2.52 Date 1/30/2020
Change % 2.44 % Price Change 0.06
Open 2.5 52 Week High 4.46
High 2.55 52 Week Low 2.4
Low 2.46 Type stock
Volume 158328 Average Volume 83575
Prev Close 2.46 Stock Exchange NYSE
Bid 2.46 Ask 2.64
Bid Size 1 Ask Size 5
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 1.647 Book Value Yield 0.6695
Buy Back Yield CAPE Ratio
Cash Return 0.0107 Cash Flow per Share 0.188
Cash Flow Yield 0.0764 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield 0.0081 EV/EBIT
EV/EBITDA EV / Free Cash Flow 93.1639
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income 107.6712
EV / Revenue 1.1047 EV / Total Asset 0.7067
Expected Dividend Growth Rate Free Cash Flow per Share 0.02
Free Caash Flow Ratio 123.178026 Free Cash Flow Yield 0.0081
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio 104.631874 Payout Ratio 0.0
PB Ratio 1.493588 PB Ratio 10 Year Growth 0.001069
PB Ratio 3 Year Growth 3.18545 Cash Ratio 3 Year Average 446.1653
Price to Cash Flow Ratio 13.083534 PEG Payback
PEG Ratio PE Ratio 123.0
PE Ratio 10 Year Average 32.768742 PE Ratio 10 Year Growth
PE Ratio 10 Year High 142.5 PE Ratio 10 Year Low 5.226804
PE Ratio 1 Year Avg 80.83354 PE Ratio 1 Year High 142.5
PE Ratio 1 Year Low 52.4 PE Ratio 3 Year Avg 46.368515
PE Ratio 5 Year Avg 32.768742 PE Ratio 5 Year High 142.5
PE Ratio 5 Year Low 5.226804 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 129.653987 Price Change 1 Month 0.935361
Price to Cash Ratio 2.056312 Price / EBITDA
Price to Sales Ratio 1.460603 Price to Sales Ratio 10 Year Growth -0.021558
Price to Sales Ratio 3 Year Avg 2.65261 Price to Sales Ratio 5 Year Avg 32.768742
Sale per Share 1.6842 Sales Yield 0.6846
Sustainable Growth Rate 0.0107 Tangible Book Value per Share 1.4716
Tangible Book Value per Share 3 year Avg 1.5227 Tangible Book Value per Share 5 year Avg 1.3944
Total Asset per Share 2.6334 Total Yield
Working Capital per Share 1.1417 Working Capital per Share 3 Year Avg 1.2929
Working Capital per Share 5 Year Avg 1.1938 Beta 1.44336